Platelets in atherogenesis
The old thrombogenic hypothesis of atherosclerosis'I 2has recently reappeared in modern costume as claims that platelets contribute to atherogenesis in three ways: first, through damaging arterial endothelial cells by releasing injurious agents, presumably where circulating platelets adhere3; second, through the release in such situations of a factor responsible for smooth muscle proliferation in the arterial wall4; and third, through the formation of persistent mural thrombi, which are organized into intimal thickenings. Such evidence as there is for these propositions fails to establish any of them as relevant to atherosclerosis in animals or human beings.5 Underlying all three claims is the assumption that some normal circulating platelets settle on arterial walls long enough to tion designed to quantify the adhesion of circulating platelets in different types of blood vessel.6 So far, the observations have been mainly on small veins. However, some observations were made also on small arteries for comparison. The venous vessels were chosen for quantification in preference to arteries because the comparative slowness of blood flow made it easier to develop and control the new methods required.
The results showed that the injection of hamster platelets, made fluorescent by labeling in vitro with fluorescein isothiocyanate, into the circulation of other hamsters makes it possible to quantify the flowing and sticking of platelets in vivo. The experiments provide evidence that there is very little tendency for circulating platelets to stick to the walls of small veins and arterioles, even under conditions in which the adhesion propensities of both platelets and vessel walls might be expected to be increased by preparative manipulations. In venules such sticking as there was affected only a very small proportion of circulating platelets and those only for very short periods. In arterioles, sticking appeared to increase somewhat under conditions in which the blood flow could be assumed to be nonlaminar. If the sticking behavior of platelets is at all similar in larger arteries, it seems unlikely that it would permit the release of platelet constituents capable of affecting the arterial walls, except just possibly under hemodynamic conditions such as occur at branches or other major unevennesses in the walls; but platelets are not normally found even there.
It is assumed further that arterial endothelium is continuously subject to "damage" or "injury" of some kind as a precondition for the adherence of platelets. There is no convincing evidence for this generalization, especially not in human beings. The With increasing size the platelet aggregates tend to constrict the cut, causing a further, although usually temporary, increase in flow velocity.
The blood-flow velocities that would be experienced by platelets closest to the vessel wall, and therefore with the highest probability of colliding with the sites of damage, can be calculated. Human platelets have a major diameter of about 1.5 gm. In an arteriole of medium size, the flow velocity of plasma and of any cells in it at a distance of 1 ,um from the wall is of the order of 10 to 100 um/msec. Therefore a platelet flowing within a distance no greater than its own diameter would pass an injury site 100 ,um long in at most 10 msec. In the absence of other influences, this would seem to be the time available for such a platelet to adhere to the damaged wall.
The time just calculated as available to circulating platelet "at risk" for adhering to a wall lesion has to be compared with what is known about the time required for platelets to be activated into a condition in which their collision with such a lesion would very probably result in adhesion. 14 That a process of activation is an essential prerequisite for adhesion and aggregation is implied by the nonreactivity of normal circulating platelets. Presumably, activation consists of a sequence of physical and biochemical events analogous to the activation of muscle.'8 The sequence is still being worked out, but several similarities with muscle are already established. Thus it is known that in platelets an early event is an increased influx of sodium unaccompanied by an equivalent amount of chloride'9 and that activation is associated with an increase of free calcium in platelets. 20' Because activation is indicated by adhesiveness, the change must involve one or more constituents of the outer surface of platelets. There is evidence that the essence is the exposure of surface receptors for fibrinogen, which has long been known to be an essential and specific plama cofactor for platelet aggregation.22 ' 23 The activation time of platelets may then be defined as the interval between the encounter of platelets with an activating agent such as ADP and their ability to react with plasma fibrinogen.
That circulating platelets can be activated to adhere in much less time than that required by their gross changes in shape, i.e., tl/2 = 1 to 2 sec at 370 C,24 is indicated by direct experimental observations. activating agent ADP by microiontophoresis to the outside of an arteriole or venule under conditions in which appropriate controls indicate that there is no evidence at all of damage to the endothelial layer.26 Platelet aggregates grow in the vessel exactly opposite the tip of the micropipette, while the blood continues to flow rapidly and without noticeable disturbance over the site. This is explained most simply by assuming that sufficient ADP diffuses between the endothelial cells into the blood to reach platelets passing close to the wall and that this ADP activates them very rapidly indeed.
An extension of this technique has provided a basis for calculating an average activation time for circulating platelets. It was found that the size of platelet aggregates produced by the iontophoretic application of ADP increases exponentially. The rate constant of this increase depended on the mean blood flow velocity, determined in the same vessels at the same time.26
The shape of the experimentally determined curve was simulated closely by a theoretical curve27 that was derived on the single assumption that platelets require an activation time of about 100 to 200 msec. This time is still one to two orders of magnitude greater than that indicated by the earlier theoretical considerations, so either this experimental derivation overestimates the true activation time or the earlier considerations failed to take something into account that would allow flowing platelets more than a few milliseconds for activation. For example, more time would be available if the blood flow near the vessel wall were nonlaminar, so that platelets caught up in vortices, however small, might be exposed to localized activating conditions for longer than they would otherwise be. When branching vessels of the microcirculation are observed microscopically, platelets can often be seen trapped in vortices for variable times of up to several seconds. Such delays may occur in the immediate vicinity of major vessel wall lesions, whether caused by disease such as the sudden rupture of an atheromatous plaque"' 28 or by traumatic injury such as a puncture or transection. However, there is no evidence of even the smallest disturbances in the flow of blood in a normal vessel in which platelets are caused to adhere by iontophoretically applied ADP. Moreover, it seems most unlikely that any endothelial unevenness produced by laser injury would give rise to flow disturbances large enough to delay the passage of platelets. The For both reactions, the equilibrium at physiologic pH is far to the right. In both species these infusions increased the bleeding times very significantly. This suggests that the observed increases in bleeding time are caused by removal from the blood plasma of ADP, the presence of which makes a major contribution to the activation and hemostatic aggregation of arriving platelets. This conclusion is supported by control experiments in which creatine phosphate was infused alone, without creatine phosphokinase. We have shown this enzyme to be present in blood plasma of both rats and rabbits, in concentrations somewhat higher than in human plasma."' Completion of the ADP-removing system by the naturally occurring plasma enzymes could therefore account for the observed increases in bleeding time in these control experiments. In each experiment, control bleeding times were measured before and after infusions of the enzyme systems. Changes in general factors that could be expected to influence bleeding time values, namely the moderate decreases in blood pressure, blood platelet concentration, and hematocrit that were observed, were thereby taken into account. There is other evidence' that the bleeding time is not affected by moderate decreases in blood platelet concentrations, i.e., as long as they remain above about 5 x 107 platelets/ml.
One reservation about the conclusion arises out of the presence of nucleotide-dephosphorylating enzymes in normal blood, both in plasma32 and as ectoenzymes on the surfaces of different types of circulating cells.33 3' These enzymes hydrolyze the y-phosphate of ATP several times more rapidly than /3-phosphate of ADP. Both of the infused enzyme systems convert ADP to ATP, which the dephosphorylating enzymes presumably reconvert into ADP. It It has recently become possible to provide more direct evidence for the presence of ADP in blood emerging from vascular injuries in experimental animals and human subjects.41 P A new technique was developed for the measurement of extracellular free ATP in very small samples of whole blood with the luciferin-luciferase enzyme system. The method had a very low background corresponding to approximately 10-16 moles of ATP. ATP was measured in blood as it emerged during hemostasis after precise puncture of rat and rabbit arteries and after standardized incisions of human skin by the Simplate device.
The initial concentration of free ATP in blood emerging 2 to 4 sec after vascular injury was about 2 X 10-7M i-n rats and rabbits and about 2 x 106M in humans. The free ATP concentration increased to about 10-5M 3 to 5 min after injury, and these increases could be prevented by heparin (20 U/ml). The source of the initial free ATP was identified as damaged cells in the injured vessel walls. It could be inferred that sufficient ADP, both released as such with ATP and generated by the rapid enzymic dephosphorylation of ATP, is present at the site of injury to initiate the hemostatic aggregation of platelets. The results confirm a long-standing proposition43 that at sites of vascular injury, enough ADP is rapidly released from damaged cells into the blood to account for the hemostatic aggregation of platelets.
Whatever the source of hemostatic ADP, its demonstration suggests novel therapeutic possibilities in the prevention of arterial thrombosis when it is initiated by platelet aggregation. One such possibility would turn on the feasibility of infusing enzyme systems that remove free ADP from the blood. In spite of immunologic and other problems, it is conceivable that one or other enzyme with this specificity and a sufficiently long half-life in blood could be investigated for this purpose in appropriate clinical conditions. Furthermore, on the basis of our demonstration that bleeding times were increased also by infusing substrates only, with the implication that the systems are completed by the endogenous plasma enzymes, it is conceivable that therapeutic removal of ADP can be achieved by administering creatine phosphate or phosphoenolpyruvate in a way that provides adequate concentrations in the circulating blood. Melvin Paul Judkins Melvin Paul Judkins died on January 28, 1985, after a day of strenuous exertion on behalf of his father-in-law, who preceded him in death by a few hours. Dr. Judkins' freely bestowed gifts reflected dedicated excellence as with his exquisite method for in vivo visualization of the coronary circulation, which is today the one most used throughout the world. It brought the "greats" and the "nameless foot soldiers" in cardiology and radiology to his laboratories a tacit tribute to his preeminence in both fields. He also shared in the development of transluminal angioplasty, which today has ever-increasing coronary application. He has literally entered the lives of thousands upon thousands, with an immensely beneficial impact. Dr 
